tradingkey.logo

Quantum BioPharma Ltd

QNTM

18.870USD

-1.120-5.60%
終値 09/19, 16:00ET15分遅れの株価
65.45M時価総額
損失額直近12ヶ月PER

Quantum BioPharma Ltd

18.870

-1.120-5.60%
詳細情報 Quantum BioPharma Ltd 企業名
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
企業情報
企業コードQNTM
会社名Quantum Biopharma Ltd
上場日May 29, 2018
最高経営責任者「CEO」Dr. Lakshmi P. Kotra, Ph.D.
従業員数- -
証券種類Ordinary Share
決算期末May 29
本社所在地55 University Ave. , Suite 1003
都市TORONTO
証券取引所Canadian Securities Exchange - CSE Listed
Canada
郵便番号M5J 2H7
電話番号14168548884
ウェブサイトhttps://www.quantumbiopharma.com/
企業コードQNTM
上場日May 29, 2018
最高経営責任者「CEO」Dr. Lakshmi P. Kotra, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
--
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
--
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 30
更新時刻: Sat, Aug 30
株主統計
種類
株主統計
株主統計
比率
Malone Wealth Ventures LLC
27.44%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
他の
62.94%
株主統計
株主統計
比率
Malone Wealth Ventures LLC
27.44%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
他の
62.94%
種類
株主統計
比率
Investment Advisor
29.99%
Individual Investor
10.58%
Research Firm
0.49%
Corporation
0.37%
Investment Advisor/Hedge Fund
0.22%
Hedge Fund
0.01%
他の
58.34%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
2023Q1
56
112.96K
18.07%
-21.18K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Malone Wealth Ventures LLC
610.37K
20.82%
+610.37K
--
Jun 23, 2025
Saeed (Zeeshan)
118.11K
4.03%
+7.69K
+6.97%
Apr 03, 2025
Durkacz (Anthony)
106.06K
3.62%
+7.69K
+7.82%
Apr 03, 2025
Carroll (Donal)
90.41K
3.08%
+7.69K
+9.30%
Apr 03, 2025
UBS Financial Services, Inc.
1.61K
0.06%
+1.61K
--
Mar 31, 2025
AdvisorShares Investments, LLC
48.99K
1.67%
-283.32K
-85.26%
Mar 31, 2025
Kotra (Lakshmi)
29.57K
1.01%
+7.69K
+35.15%
Apr 03, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
AdvisorShares Psychedelics ETF
9.38%
AdvisorShares Psychedelics ETF
比率9.38%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
日付
種類
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
KeyAI